Clinical Trials on Safety Evaluation of Escalating Doses in New Zealand
Total 22 results
-
University of RochesterAgency for Healthcare Research and Quality (AHRQ)CompletedCompletion of Three Dose Series of HPV | Improvement in Vaccine Intervals Between HPV DosesUnited States
-
BeiGeneRecruitingLocally Advanced or Metastatic Solid Tumors for Phase 1,Dose Escalation and Phase 2 Safety Lead-in, HNSCC, NSCLC and RCC Participants for Phase 2Australia, United States, Spain, France, Italy, Korea, Republic of, Poland
-
RWTH Aachen UniversityCompleted
-
EndologixActive, not recruitingSafety and Performance of the Nellix Endovascular Sealing SystemGermany, Latvia, Luxembourg, Netherlands, New Zealand, Norway, Sweden, United Kingdom
-
Englewood Hospital and Medical CenterTerminated
-
Kythera BiopharmaceuticalsCompletedEfficacy | Safety | Moderate to Severe Convexity of Submental FatUnited States
-
Biotronik AGCompletedLong Term Safety of the AMS 1.0Switzerland, Germany, Australia, Belgium, Netherlands
-
Columbia UniversityTerminatedPain | Evaluating Pharmacokinetics of Intranasal KetorolacUnited States
-
Biotronik, Inc.CompletedSafety of the ProMRI Pacemaker System Under Specific MRI ConditionsUnited States
-
Biotronik, Inc.TerminatedSafety and Effectiveness of the Siello S LeadUnited States
-
Vanda PharmaceuticalsCompletedSafety and Tolerability of IloperidoneUnited States
-
Population Health Research InstituteCharles University, Czech Republic; Centre hospitalier de l'Université de Montréal... and other collaboratorsCompletedthe Efficacy and Safety of Off-pump CABGCanada, China, Colombia, India, Chile, Argentina, Brazil, Czech Republic, France, Italy, Poland, Turkey, United Kingdom
-
Biotronik SE & Co. KGCompletedSafety of MR (Magnetic Resonance) Conditional CRT-pacemakers and ICDsFrance, Germany, Hungary, Canada, Australia, Austria, Czech Republic, Switzerland
-
Albert Einstein College of MedicineRecruitingSafety and Efficacy of Radiation Therapy for the Treatment of KeloidsUnited States
-
ModernaTX, Inc.AstraZenecaActive, not recruitingDose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma | Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC LymphomaUnited States, Israel, Australia
-
University Hospitals Cleveland Medical CenterWashington University School of Medicine; Case Western Reserve University; Papua... and other collaboratorsRecruitingLymphatic Filariasis Elimination by Mass Drug Administration | Monitoring and Evaluation of Mass Drug Administration for Lymphatic Filariasis | Acceptability of Mass Drug Administration for Lymphatic FilariasisPapua New Guinea
-
Novartis PharmaceuticalsUniversity of PennsylvaniaRecruitingLong Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access ProgramUnited States, Japan, Australia, Germany, Spain, Belgium, Taiwan, Italy, Canada, Israel, Singapore, United Kingdom, Denmark, Finland, Norway, Austria, Netherlands, France
-
Novartis PharmaceuticalsCompletedLong-term Safety of TIPItaly, Spain, Germany, United States, Australia, Canada, Hungary, Mexico, Argentina
-
RWTH Aachen UniversityTerminatedEfficacy and Safety of Xenon Inhalation | Successful Cardiopulmonary Resuscitation | Addition to Therapeutical HypothermiaGermany
-
AmgenCompletedEvaluate the Safety and Efficacy of Denosumab in Pediatric Subjects With | Glucocorticoid-induced OsteoporosisUnited States, Bulgaria, Turkey, Italy, Australia, Belgium, Canada, Colombia, India, Mexico, Peru, Russian Federation, Ukraine
-
Novartis PharmaceuticalsCompletedParkinson's Disease With End of Dose Wearing OffUnited States, Puerto Rico
-
Axcella Health, IncCompletedSickle Cell Disease | Anemia, Sickle Cell | Sickle Cell Anemia | To Assess the Safety and Tolerabiltiy of an Amino Acid Composition in Subjects With Sickle Cell Disease | Sickle Cell DisordersUnited States